Quick summary of Endo's...webacast presentation at Citi's Global HC conference this morn...
No mention of Urocidin. The focus of Endo's presentation strictly on 2012 outlook/ activities to increase value in this timeframe Hence, pipeline launches beyond 2012 were outside the scope of presentation. Also, no slide on "pipeline" and no analyst questions as part of the webcast.
See link to Endo's PPT of presentation (in 8-k form just released):
On a positive note, several mentions to related strategy that supports the longer-term importance of Urocidin for Endo: Few excerpts from presentation (possibly not word-for-word as scribbled notes)...
- "particuliar focus on pain management and urology"
- "strengthen (in 2012) leadership position in urology"
and, "diversification strategy" emphasized several times throughout presentaion as working.
Certainly disappointed not to hear a bit of an update on Urocidin.
Nevertheless, I much prefer that Endo is "quietly" taking very supportive "action" with their current investment to Urocidin's ongoing second phase III clinical trial (a potential investment between $60-80 million for this trial depending on source).
Talk can be very cheap... Actual $ spending = BIG commitment. That's all need to $ee.
Have a good one, rg P.S... next Endo webcast at a HC conference:
 |
Webcast
ENDO PHARMACEUTICALS HLDGS INC at Cowen Group Health Care Conference (Live)
03/07/12 at 10:40 a.m. ET
And, Endo was just upgraded by Cowen this morn...
|
Endo Pharmaceuticals upgraded to Outperform from Neutral at Cowen
Theflyonthewall.com
Cowen upgraded Endo Pharmaceuticals citing valuation, expectations for a favorable Lidoderm outcome, and its diversification strategy.